Containing Natural Gums Or Resins Patents (Class 424/481)
  • Publication number: 20150132378
    Abstract: The present invention relates to a multilayered coated tablet comprising at least three layers, i.e., first, second and third layer wherein the first and third layers contain at least one active pharmaceutical ingredient and the second layer is either a placebo or an immediate-release drug layer. Further, the tablet has a delayed-release coating, wherein the coating may contain one or more pore-forming agents and/or orifices on one or both sides. Furthermore, it may contain an immediate-release layer of the drug over the delayed-release coating layer. The present invention further relates to processes for preparing such a multilayered coated tablet.
    Type: Application
    Filed: June 29, 2012
    Publication date: May 14, 2015
    Applicant: RANBAXY LABORATORIES LIMITED
    Inventors: Murali Krishna Bhavarisetti, Kumaravel Vivek, Sreekanth Narravula, Romi Barat Singh
  • Patent number: 8945619
    Abstract: Drugs are formulated as oral dosage forms for controlled release in which the release rate limiting portion is a shell surrounding the drug-containing core. The shell releases drug from the core by permitting diffusion of the drug from the core. The shell also motes gastric retention of the dosage form by swelling upon imbibition of gastric fluid to size that is retained in the stomach during the postprandial or fed mode.
    Type: Grant
    Filed: November 28, 2012
    Date of Patent: February 3, 2015
    Assignee: Depomed, Inc.
    Inventors: Bret Berner, Jenny Louie-Helm, Gloria Gusler, John N. Shell
  • Patent number: 8933081
    Abstract: The invention relates to an orodispersible tablet comprising the components pharmaceutically acceptable sildenafil salt (a), polymeric adsorbent (b), in particular cation exchanger resin, sweetener (c), and flavoring (d) and, preferably, mucilage (e) and glidant (f). The invention furthermore relates to a process for the preparation of orodispersible tablets comprising a pharmaceutically acceptable sildenafil salt and to the use of a combination of cation exchanger resin and mucilage for masking the flavor of medicaments for treating erectile dysfunction.
    Type: Grant
    Filed: March 31, 2010
    Date of Patent: January 13, 2015
    Assignee: ratiopharm GmbH
    Inventors: Sven Winter, Max-Werner Scheiwe
  • Patent number: 8722089
    Abstract: The present invention features a method of making a coated tablet by dipping a core comprising an active agent into a coating liquid and drying said dipped core to form a outer-coating on the core, wherein the coating liquid contains at least one a starch having an amylose content of at least about 50 percent by weight of said starch.
    Type: Grant
    Filed: February 17, 2009
    Date of Patent: May 13, 2014
    Assignee: McNeil-PPC, Inc.
    Inventor: Jen-Chi Chen
  • Publication number: 20130084333
    Abstract: Aspects of the present invention are directed to abuse resistant oral dosage forms comprising a compressed microtablet that is coated with a water-retardant polymer. Additional aspects of the present invention are directed to an oral dosage form comprising an opioid agonist and at least one compressed microtablet coated with a water retardant polymer. The compressed microtablet may comprise an opioid antagonist.
    Type: Application
    Filed: June 25, 2010
    Publication date: April 4, 2013
    Applicant: ELITE LABORATORIES, INC
    Inventors: Christopher C. Dick, David F. Erkoboni, Charanjit R. Behl, Gary Bubb
  • Patent number: 8399017
    Abstract: A tablet for oral administration comprises a matrix of progressive and continuous released magnesium. For the administration of 90 to 110 parts by weight of magnesium, the matrix comprises 180 to 190 parts by weight of hydroxypropylmethylcellulose, 19.8 to 22.2 parts by weight of glyceryl behenate, 10 to 12 parts by weight of lactose and 10 to 12 parts by weight of colloidal silica. A non-enteric protective coating that slows down the gastric dissolution of the magnesium may comprise 15 to 75 parts by weight of shellac, cellulose ether or a mixture thereof. The tablet may be administered to patients in need thereof.
    Type: Grant
    Filed: May 20, 2009
    Date of Patent: March 19, 2013
    Inventor: Fabienne Joanny
  • Patent number: 8329216
    Abstract: The invention pertains to a method of relieving pain by administering a controlled release pharmaceutical tablet containing oxymorphone which produces a mean minimum blood plasma level 12 to 24 hours after dosing, as well as the tablet producing the sustained pain relief.
    Type: Grant
    Filed: June 29, 2006
    Date of Patent: December 11, 2012
    Assignee: Endo Pharmaceuticals Inc.
    Inventors: Haui-Hung Kao, Anand R. Baichwal, Troy McCall, David Lee
  • Patent number: 8309122
    Abstract: The invention pertains to a method of relieving pain by administering a controlled release pharmaceutical tablet containing oxymorphone which produces a mean minimum blood plasma level 12 to 24 hours after dosing, as well as the tablet producing the sustained pain relief.
    Type: Grant
    Filed: February 28, 2007
    Date of Patent: November 13, 2012
    Assignee: Endo Pharmaceuticals Inc.
    Inventors: Huai-Hung Kao, Anand R. Baichwal, Troy McCall, David Lee
  • Publication number: 20120237599
    Abstract: The disclosure provides oral cysteamine and cystamine formulations useful for treating cystinosis and neurodegenerative diseases and disorders. The formulations provide controlled release compositions that improve quality of life and reduced side-effects.
    Type: Application
    Filed: February 17, 2012
    Publication date: September 20, 2012
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Ranjan Dohil, Jerry Schneider
  • Publication number: 20120189693
    Abstract: Aspects of the present invention are directed to oral dosage forms comprising a compressed microtablet, wherein said microtablet has a major dimension that is between about 0.25 mm and about 1.0 mm and comprises at least about 0.01 weight percent of at least one pharmaceutically active agent that is distributed substantially throughout said microtablet. Additional aspects of the present invention are directed to methods for producing compressed microtablets having a major dimension that is between about 0.25 mm and about 1.0 mm.
    Type: Application
    Filed: June 25, 2010
    Publication date: July 26, 2012
    Applicant: Elite Laboratories, Inc.
    Inventors: Christopher C. Dick, David F. Erkoboni, Charanjit R. Behl, Gary Bubb
  • Publication number: 20120082723
    Abstract: It is an object to provide a coating composition, which is used for an orally-administered preparation, the administering property of which has been improved, and/or an easily administrable preparation that does not affect dissolution property. The aforementioned object can be achieved using a coating composition comprising a first thickener selected from the group consisting of a carboxyvinyl polymer and sodium alginate, a polyvalent metal compound, and at least one type of a second thickener selected from the group consisting of xanthan gum, guar gum and sodium alginate, with the proviso that when the first thickener is sodium alginate the second thickener is not sodium alginate, or using a coating composition comprising, as thickeners, hydroxypropylmethylcellulose and sugar or sugar alcohol having a solubility at 20° C. of 30 or more.
    Type: Application
    Filed: September 30, 2011
    Publication date: April 5, 2012
    Inventors: Yumio Kudou, Kuniomi Warabino
  • Patent number: 8076279
    Abstract: The present invention is related to the use of a non-cellulosic cationically modified polysaccharide in cleaning compositions and more particularly to a surfactant based cleansing composition comprising, a surfactant, a non-cellulosic cationically modified polysaccharide and a solvent for use in personal care composition, household care composition or an institutional care composition.
    Type: Grant
    Filed: October 9, 2009
    Date of Patent: December 13, 2011
    Assignee: Hercules Incorporated
    Inventors: Piet Brand, Richard G. Brown, Anita N. Chan, Paquita Erazo-Majewicz, Jashawant J. Modi
  • Publication number: 20110274753
    Abstract: Dual release oral tablet compositions of dexlansoprazole or pharmaceutically acceptable salts or hydrated forms thereof and processes for the manufacture of the tablet composition and its use in the treatment of gastrointestinal disorders.
    Type: Application
    Filed: May 5, 2011
    Publication date: November 10, 2011
    Applicant: Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi
    Inventors: Umit Cifter, Ali Turkyilmaz, Ibrahim Murat Uzer, Alper Terkinli, Levent Oner
  • Patent number: 8017032
    Abstract: A solid composition in the form of a tablet that generates and releases a biocidal solution comprising at least chlorine dioxide with an enhanced weight percent yield is presented. The composition comprises reactants capable of in-situ generation of chlorine dioxide comprising a chlorite donor that is coated with a gel-forming material that slows the rate of dissolution of the high solubility chlorite donor, a free halogen donor, and an acid source, resulting in an unexpectedly high weight percent yield and providing a controlled release of biocidal solution. The compositions of the invention show improved environmental stability which can reduce the cost of packaging and significantly increase the utility of the composition. The controlled release allows the use in multi-tablet chemical dispensers which may otherwise induce potentially explosive conditions or allow rapid release of the biocidal solution thereby inducing a spike in chemical concentration rather than a controlled and sustained release.
    Type: Grant
    Filed: August 25, 2010
    Date of Patent: September 13, 2011
    Assignee: Truox, Inc.
    Inventor: Roy W. Martin
  • Publication number: 20110195121
    Abstract: This invention relates to a pharmaceutical dosage form for the phase-controlled and chronotherapeutic delivery of at least one and, preferably, several pharmaceutically active ingredients. The dosage form has a carrier platform which,—preferably, is a polymer having known biodegradable characteristics. The platform may include a pharmaceutically active ingredient'which is released over a predetermined period of time as the platform polymer degrades. At least one pharmaceutically active ingredient in the form of a disc is embedded in the platform and, once the polymer of the platform has degraded, the disc is released and releases its ingredient in the same location as that of the platform or it travels to another region of the body where it releases its ingredient.
    Type: Application
    Filed: June 3, 2009
    Publication date: August 11, 2011
    Inventors: Seshni Sewlall, Viness Pillay, Yahya Choonara, Zaheeda Khan
  • Patent number: 7993545
    Abstract: A solid composition in the form of a tablet that generates and releases a biocidal solution comprising at least chlorine dioxide with an enhanced weight percent yield is presented. The composition comprises reactants capable of in-situ generation of chlorine dioxide comprising a chlorite donor that is coated with a gel-forming material that slows the rate of dissolution of the high solubility chlorite donor, a free halogen donor, and an acid source, resulting in an unexpectedly high weight percent yield and providing a controlled release of biocidal solution. The compositions of the invention show improved environmental stability which can reduce the cost of packaging and significantly increase the utility of the composition. The controlled release allows the use in multi-tablet chemical dispensers which may otherwise induce potentially explosive conditions or allow rapid release of the biocidal solution thereby inducing a spike in chemical concentration rather than a controlled and sustained release.
    Type: Grant
    Filed: June 2, 2010
    Date of Patent: August 9, 2011
    Assignee: Truox, Inc.
    Inventor: Roy W. Martin
  • Patent number: 7985427
    Abstract: The invention relates to a gastric juice-resistant device for releasing active substance excipients having delayed intestinal passage from a gastric juice-resistant enclosure, and which serves to increase the active substance concentration in the intestines. The inventive device is characterized in that the active substance excipient containing at least one active substance is provided in the form of a multiparticulate preparation whose individual particles have mucoadhesive properties. The invention also relates to a method for producing said device.
    Type: Grant
    Filed: April 22, 2002
    Date of Patent: July 26, 2011
    Assignee: LTS Lohmann Therapie-Systeme AG
    Inventors: Despina Solomonidou, Markus Krumme, Bodo Asmussen, Joerg Kreuter
  • Patent number: 7785650
    Abstract: Water soluble, gelatin-free dip coatings for pharmaceutical solid dosage forms such as tablets comprising HPMC and xanthan gum, carrageenan, and mixtures thereof, or HPMC and castor oil or maltodextrin.
    Type: Grant
    Filed: June 27, 2007
    Date of Patent: August 31, 2010
    Assignee: McNeil-PPC, Inc.
    Inventors: Cynthia Gulian, Walter G. Gowan, Jr., Kishor B. Parekh, Joseph M. Morris, Thomas J. Markley, Dennis C. Wieand, Gerard P. McNally, Christopher Szymczak
  • Patent number: 7749537
    Abstract: A method of forming a tablet includes the steps of pre-blending an active pharmaceutical ingredient susceptible to tackiness and a blending additive with a first mixing effort to form a pre-blend mixture, wherein the first mixing effort and a second mixing effort, resulting from mixing at least one excipient with the pre-blend mixture, form a blend suitable for direct compression and compressing the blend to form the tablet. One way of achieving the first mixing effort is to pre-blend for an extended period of time. The method allows for directly compressing the blend without the need for a granulation step or roller compression. One such active pharmaceutical ingredient susceptible to tackiness is ibuprofen.
    Type: Grant
    Filed: October 1, 2007
    Date of Patent: July 6, 2010
    Assignee: SCOLR Pharma, Inc.
    Inventors: Michael Hite, Cathy Federici, Alan Brunelle, Stephen Turner
  • Patent number: 7727552
    Abstract: A composition of an oral medicine or an oral medicine which can prevent an unpleasant taste of the medicine is herein disclosed. It is granules, powders, syrups and the like which is prevented from an unpleasant taste, comprising a basic medicine having an unpleasant taste and an anionic polymer such as carrageenan.
    Type: Grant
    Filed: March 26, 1998
    Date of Patent: June 1, 2010
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Koji Ukai, Tsutomu Hrada, Yasuyuki Suzuki
  • Patent number: 7510729
    Abstract: The invention relates to the combination of polyvinyl acetate and water-insoluble, acid-insoluble, or alkali-insoluble polymers used for producing film coatings for forms of administration in which agents are released in a controlled manner, and methods for the production thereof. The controlled-release properties can be specifically adjusted by means of said combinations, resulting in films having excellent mechanical stability and storage stability. In particular, agents are released independent of the pH by means of the inventive forms of administration.
    Type: Grant
    Filed: March 11, 2003
    Date of Patent: March 31, 2009
    Assignee: BASF Aktiengesellschaft
    Inventors: Karl Kolter, Roland Bodmeier, Andriy Dashevskiy
  • Publication number: 20090074866
    Abstract: In one aspect, the present invention features a method of making a coated tablet, by dipping a core including an active agent into a coating liquid and drying the dipped core to form a outer-coating on said core, wherein the coating liquid includes (i) at least one copolymer of polyvinyl alcohol and polyethylene glycol, (ii) at least one gum, and (iii) a solvent for the at least one copolymer of polyvinyl alcohol and polyethylene glycol and the at least one gum and coated tablets manufactured by such method.
    Type: Application
    Filed: September 15, 2008
    Publication date: March 19, 2009
    Inventor: Jen-Chi Chen
  • Publication number: 20080260828
    Abstract: This invention relates to solid and stable dispersions of a hydrosoluble derivative of vinca alkaloids in at least one polyethyleneglycol with a molecular mass between 800 and 30,000.
    Type: Application
    Filed: April 14, 2008
    Publication date: October 23, 2008
    Applicant: Pierre Fabre Medicament
    Inventors: Joel Bougaret, Eli LEVERD, Marie-Dominique Ibarra
  • Patent number: 7276250
    Abstract: Sustained release formulations of oxymorphone or pharmaceutically acceptable salts thereof; methods for making the sustained release formulations of oxymorphone or pharmaceutically acceptable salts thereof; and methods for using the sustained release formulations of oxymorphone or pharmaceutically acceptable salts thereof to treat patients suffering from pain are provided.
    Type: Grant
    Filed: July 3, 2002
    Date of Patent: October 2, 2007
    Assignee: Penwest Pharmaceuticals Company
    Inventors: Anand R. Baichwal, Huai-Hung Kao, Troy W. McCall
  • Publication number: 20070215511
    Abstract: A coated drug-ion exchange resin complex comprising a core composed of a drug complexed with a pharmaceutically acceptable ion-exchange resin is provided. The drug-ion exchange resin complex is in admixture with a release retardant. The coating is a polyvinyl acetate polymer and a plasticizer. Methods of making and products containing this coated complex are described.
    Type: Application
    Filed: March 15, 2007
    Publication date: September 20, 2007
    Applicant: Tris Pharma, Inc.
    Inventors: Ketan Mehta, Yu-Hsing Tu
  • Patent number: 7229642
    Abstract: Disclosed herein is a oral extended release dosage form comprising a plurality of granules of an effective amount of a pharmaceutically active compound, at least one amino acid, and an intragranular polymer in which the granule is dispersed within a hydrophilic extragranular polymer matrix which is more rapidly hydrating than the intragranular polymer. The amino acid is selected for hydropathy characteristics depending on solubility characteristics of the active compound.
    Type: Grant
    Filed: June 22, 2005
    Date of Patent: June 12, 2007
    Assignee: Scolr, Inc.
    Inventors: A. Reza Fassihi, Thomas Dürig
  • Patent number: 7214387
    Abstract: The invention provides sustained release formulations of metformin or a pharmaceutically acceptable salt thereof, and methods of treating diabetes by administering to a patient a therapeutically effective amount of a sustained release formulation of metformin or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: July 30, 2003
    Date of Patent: May 8, 2007
    Assignee: Penwest Pharmaceuticals Company
    Inventors: Pradeep P. Sanghvi, Sara Ketsela
  • Patent number: 7195769
    Abstract: A pharmaceutical composition of anti-tubercular drugs for oral use comprising Rifampicin and/or Isoniazid wherein the bioavailability of Rifampicin and/or other drugs is enhanced. Preferably the bioavailability of Rifampicin is enhanced by preventing its degradation caused by presence of Isoniazid. Rifampicin and/or Isoniazid may be present in delayed release and/or extended release form such that minimal amount of the drug is dissolved between pH 1 and 4. preferably delayed release of Rifampicin and/or Isoniazid is achieved by treating the drugs with pH sensitive polymers.
    Type: Grant
    Filed: April 10, 2001
    Date of Patent: March 27, 2007
    Assignee: Panacea Biotec Limited
    Inventors: Amarjit Singh, Rajesh Jain
  • Patent number: 6994873
    Abstract: This invention refers to: multiparticulate formulations of Lithium salts for oral administration constituted by either modified release granules or mixtures of modified and conventional release granules, suitable for once-a-day administration also at high strengths of Lithium salts, and to the preparation process of said formulations.
    Type: Grant
    Filed: February 4, 2002
    Date of Patent: February 7, 2006
    Assignee: Valpharma S.A.
    Inventors: Roberto Valducci, Tiziano Alighieri, Serozh Avanessian
  • Publication number: 20040129174
    Abstract: A composition comprising a high molecular weight, water soluble polymer having a cloud point from about 20 to about 90° C. and at least one carrageenan is provided. The composition may be used as a component of a pharmaceutical dosage form, such as the shell of a dosage form, to provide burst release of active ingredient contained therein.
    Type: Application
    Filed: October 28, 2003
    Publication date: July 8, 2004
    Inventors: Shun-Por Li, Der-Yang Lee, Frank J. Bunick, Jen Chi Chen, Harry S. Sowden
  • Patent number: 6753012
    Abstract: The invention provides a process for coating a branded pharmaceutical dosage form for the purpose of covering any embossed or printed matter or any colored coating by the application of an amount of a sugar based coating which is sufficient to obscure any identifying indicia without compromising the stability or releasability of the drug that is contained in the dosage form.
    Type: Grant
    Filed: July 31, 2002
    Date of Patent: June 22, 2004
    Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventor: Michael L. Cappola
  • Patent number: 6747072
    Abstract: The present invention provides an ink composition for use in ink jet printing on food items, candy, particularly dark candy, such as chocolate, and to a method of forming printed images on such food items by use of the ink compositions. The compositions of the present invention comprise a pigment, a binder, and an aqueous carrier.
    Type: Grant
    Filed: January 22, 1997
    Date of Patent: June 8, 2004
    Assignee: Marconi Data Systems Inc.
    Inventor: Mohammed W. Siddiqui
  • Publication number: 20040103821
    Abstract: There are provided an aqueous shellac coating agent comprising shellac, a basic amino acid and/or a basic phosphate, as well as a production process therefor; a coated food and a coated drug that have been coated with such a coating agent; a glazing composition for oil-based confectionary which is in a liquid form and comprises an aqueous shellac solution (A) containing shellac, a basic amino acid and/or a basic phosphate dissolved in water, a thickener (B), and/or a sugar (C); a process for glazing oil-based confectionary in which this glazing composition is applied to oil-based confectionary to be glazed, thereby generating a glaze; and glazed oil-based confectionary produced using this process for glazing oil-based confectionary.
    Type: Application
    Filed: November 25, 2003
    Publication date: June 3, 2004
    Applicant: Freund Industrial Co., Ltd.
    Inventors: Tomoyuki Shobu, Kazuo Igusa, Toshichika Ogasawara
  • Patent number: 6709677
    Abstract: Sustained release oral solid dosage forms comprising agglomerated particles of a therapeutically active medicament in amorphous form, a gelling agent, an ionizable gel strength enhancing agent and an inert diluent, as well as processes for preparing and using the same are disclosed. The sustained release oral solid dosage forms are useful in the treatment of hypertension in human patients.
    Type: Grant
    Filed: June 12, 2001
    Date of Patent: March 23, 2004
    Assignee: Penwest Pharmaceuticals Co.
    Inventor: Anand Baichwal
  • Patent number: 6709678
    Abstract: An oral composition which is adapted to be dispersed in an aqueous carrier substantially immediately prior to administration comprises a multiplicity of particles comprising an active substance, the particles being combined with one or more gelling or swelling agents capable of forming a viscous medium around the particles in an aqueous carrier as well as being provided with a masking surface layer when dispersed in the aqueous carrier. This serves to mask uneven surfaces on the particles and prevent them from adhering to oral mucosa when the composition is ingested and thus makes it easier to administer large dosages of an active substance. The masking surface layer is preferably provided by an increased viscosity of the viscous medium in the immediate vicinity of the particles relative to the viscosity of the surrounding aqueous carrier. A ready-to-use composition is prepared by mixing the composition with an aqueous carrier substantially immediately prior to administration of the composition.
    Type: Grant
    Filed: February 10, 1999
    Date of Patent: March 23, 2004
    Assignee: Losan Pharma GmbH
    Inventor: Peter Gruber
  • Patent number: 6706284
    Abstract: The invention relates to an oral pharmaceutical composition which has excellent drug release-controlling ability in the mouth even 5 to 10 minutes after its administration and also has excellent drug releasing ability in the digestive tract without using capsules. It also relates to an oral pharmaceutical composition which comprises one or more drugs having a bitter taste, one or more solid proteins, and one or more pharmaceutically acceptable polymer bases, wherein the proteins are present in the polymer bases preferably as particles.
    Type: Grant
    Filed: March 14, 2002
    Date of Patent: March 16, 2004
    Assignee: Yamanouchi Pharmaceutical Co., Ltd.
    Inventors: Masahiro Yanagisawa, Takao Mizumoto
  • Patent number: 6673369
    Abstract: The present invention relates to a controlled release pharmaceutical composition comprising amounts ranging from about 0.1 to about 4.5% w/w, of one or more of rate controlling cellulosic ether polymers.
    Type: Grant
    Filed: January 22, 2002
    Date of Patent: January 6, 2004
    Assignee: Ranbaxy Laboratories Limited
    Inventors: Ashok Rampal, Rajeev S. Raghuvanshi, Manoj Kumar
  • Publication number: 20030235617
    Abstract: A pharmaceutical tablet is provided comprising an intraorally disintegratable core and an excipient coating adherent thereto, wherein the coating comprises gellan gum. The tablet is suitable for intraoral administration, for example for delivery of a drug contained in the core of the tablet to a subject, at least in part by absorption of the drug via oral mucosa of the subject.
    Type: Application
    Filed: February 6, 2003
    Publication date: December 25, 2003
    Inventors: Alice C. Martino, Steven A. Pierman, Robert M. Noack, Nancy J. Britten
  • Patent number: 6663896
    Abstract: A method and controlled release oral unit dosage form of acetylsalicylic acid (aspirin) delays the release of the drug until a predetermined time interval after ingestion. This enables the drug to reach optimal therapeutic blood levels at a time in the early morning when the events leading up to a vascular obstruction culminating in a heart attack or stroke are most commonly occurring after the drug is taken in the evening. The convenience of taking the drug every evening should enhance compliance. By arranging for the optimal blood level to coincide with the peak incidence of strokes, a much smaller total dose of the drug may be used than is normally prescribed. This may reduce the incidence of side effects that are dose related. This will make the prophylactic use of aspirin available to more of the population.
    Type: Grant
    Filed: August 1, 2001
    Date of Patent: December 16, 2003
    Inventor: Alvin S. Blum
  • Publication number: 20030211156
    Abstract: A novel oral dosage to be delivered to the stomach comprising a safe and effective amount of an active ingredient selected from the group consisting of emepronium bromidebromide, doxycycline, and other tetracyclines/antibiotics, iron preparations, quinidine, nonsteroidal anti-inflammatory drugs, alprenolol, ascorbic acid, captopril, theophylline, zidovoudine (AZT), bisphosphonates and mixtures thereof and pharmaceutically-acceptable excipients, wherein said oral dosage form is a generally oval form and film coated to facilitate rapid esophageal transit and avoid irritation in the mouth, buccal cavity, pharynx, and esophagus.
    Type: Application
    Filed: March 28, 2003
    Publication date: November 13, 2003
    Applicant: The Procter & Gamble Company
    Inventors: Richard John Dansereau, Petrus Jakobus Bekker
  • Patent number: 6645509
    Abstract: The present invention relates to a cosmetic or pharmaceutical composition comprising, in a physiologically acceptable medium, a purified natural or synthetic epidermis-specific polypeptide which is involved in horny layer cell cohesion. The invention also relates to a cosmetic or pharmaceutical composition comprising a mixture of polypeptides derived from the proteolysis of the purified polypeptide of the present invention. The present invention further relates to a method for strengthening horny layer cell cohesion which comprises applying the cosmetic or pharmaceutical composition of the present invention to the skin. Finally, the present invention relates to a method for reducing horny layer cell cohesion, and thereby promoting exfoliation, wherein said method comprises applying to the skin a cosmetic or pharmaceutical composition comprising an effective amount of at least one protease active on the polypeptide of the present invention.
    Type: Grant
    Filed: December 29, 1999
    Date of Patent: November 11, 2003
    Assignee: Societe L'Oreal S.A.
    Inventors: Guy Bruno Rene Serre, Michel Simon, Marina Weber-Vivat
  • Patent number: 6635282
    Abstract: A film coated tablet wherein the tablet is film coated with a gellan gum coating composition containing gellan gum, a plasticizer, and a disintegration aid. Optionally a slip enhancer is added to the composition. A method for coating a tablet with the gellan gum composition wherein the composition is applied as a solution. A method of administering the gellan gum film coated tablet as a pharmaceutical.
    Type: Grant
    Filed: May 12, 2000
    Date of Patent: October 21, 2003
    Assignee: Pharmacia Corporation
    Inventors: John Flanagan, George Colegrove, Thierry Nivaggioli
  • Patent number: 6627225
    Abstract: A pharmaceutical composition comprising a tablet having a dried coating thereon, wherein the composition has a total weight of about 100 mg to about 1.5 g, the dried coating comprises about 0.
    Type: Grant
    Filed: April 30, 2002
    Date of Patent: September 30, 2003
    Assignee: Pharmacia Corporation
    Inventors: John Flanagan, George Colegrove, Thierry Nivaggioli
  • Publication number: 20030180357
    Abstract: A pharmaceutical tablet is provided comprising a core and a coating adherent thereto, wherein (a) the core comprises solid particles of a water-soluble dye distributed in a matrix, and (b) the coating comprises gellan gum. The tablet is suitable for peroral or intraoral administration, for example for delivery of a drug contained in the core of the tablet to a subject. The tablet has a speckled appearance that renders the tablet readily identifiable.
    Type: Application
    Filed: February 6, 2003
    Publication date: September 25, 2003
    Inventors: Alice C. Martino, Robert M. Noack, Steven A. Pierman
  • Patent number: 6558707
    Abstract: The invention relates to oral pharmaceutical compositions useful as aldosterone receptor blockers comprising the active agent micronized eplerenone in an amount of about 10 mg to about 1000 mg and one or more carrier materials.
    Type: Grant
    Filed: March 19, 2002
    Date of Patent: May 6, 2003
    Assignee: G. D. Searle & Co.
    Inventors: Shilpa S. Thosar, Rajeev D. Gokhale, Dwain S. Tolbert
  • Patent number: 6555138
    Abstract: A drug delivery system for oral administration in solid dry form of greasy/oily/sticky substance(s) and pharmaceutically active substance(s) or pharmaceutically active substance(s) which itself/themselves is/are greasy/oily/sticky) characterized by having a plurality of solid, polymeric matrix beads comprising considerable amounts of greasy/oily/sticky substances and having fast release characteristics and a process for the preparation of such solid, polymeric matrix beads comprising greasy/oily/sticky substances.
    Type: Grant
    Filed: January 4, 1999
    Date of Patent: April 29, 2003
    Assignee: AstraZeneca AB
    Inventors: Christer Karlsson, Per Johan Lundberg, Adam Rosinski, Malin Söderbom
  • Patent number: 6555136
    Abstract: Novel pharmaceutical dosage forms provide for pulsatile delivery of methylphenidate, i.e., release encapsulated drug in spaced apart “pulses.” The dosage forms are comprised of first, second and optionally third dosage units, with each dosage unit having a different drug release profile. The dosage forms may comprise capsules housing compressed tablets or drug-containing beads or particles, or may comprise a single tablet with the first, second and optionally third dosage units each representing an integral and discrete segment thereof. Methods of treatment using the pharmaceutical dosage forms are provided as well.
    Type: Grant
    Filed: November 13, 2001
    Date of Patent: April 29, 2003
    Assignee: PharmaQuest, Ltd.
    Inventor: Kamal K. Midha
  • Patent number: 6531155
    Abstract: Granular materials are obtainable by pressing mixtures of at least one pulverulent, rheology-modifying, carboxyl-containing polymer as main component and at least one oil-soluble component.
    Type: Grant
    Filed: July 6, 1998
    Date of Patent: March 11, 2003
    Assignee: BASF Aktiengesellschaft
    Inventors: Christian Schade, Robert Heinz, Thekla Börs, Hans-Ulrich Wekel
  • Patent number: 6506405
    Abstract: In accordance with the present invention, there are provided composition and methods useful for the in vivo delivery of a pharmaceutically active agent, wherein the agent is associated with a polymeric biocompatible material.
    Type: Grant
    Filed: August 1, 2000
    Date of Patent: January 14, 2003
    Assignee: American BioScience, Inc.
    Inventors: Neil P. Desai, Patrick Soon-Shiong
  • Patent number: 6500454
    Abstract: A unit dosage form, such as a capsule or the like for delivering drugs into the body in a circadian release fashion, is comprising of one or more populations of propranolol-containing particles (beads, pellets, granules, etc.). Each bead population exhibits a pre-designed rapid or sustained release profile with or without a predetermined lag time of 3 to 5 hours. Such a circadian rhythm release cardiovascular drug delivery system is designed to provide a plasma concentration—time profile, which varies according to physiological need during the day, i.e., mimicking the circadian rhythm and severity/manifestation of a cardiovascular disease, predicted based on pharmaco-kinetic and pharmaco-dynamic considerations and in vitro/in vivo correlations.
    Type: Grant
    Filed: October 4, 2001
    Date of Patent: December 31, 2002
    Assignee: Eurand Pharmaceuticals Ltd.
    Inventors: Phillip J. Percel, Krishna S. Vishnupad, Gopi M. Venkatesh